Skip to main content
Past Event

Conference on Clinical Cancer Research

The 2009 Conference on Clinical Cancer Research, hosted by the Engelberg Center for Health Care Reform and Friends of Cancer Research, brought together distinguished members of the cancer community for in-depth discussions of critical issues at the intersection of clinical research and policy.

The all-day event on September 14 convened leaders from the National Cancer Institute (NCI), academia, patient advocacy organizations, the Food and Drug Administration (FDA), and various industry organizations, to discuss specific research and policy issues, as well as build consensus around solutions to critical questions regarding the future of clinical cancer research.

Opening remarks were delivered by NCI Director John Niederhuber, with keynote remarks offered by FDA Commissioner Margaret Hamburg. Interactive panel discussions focused on optimal data collection for clinical trials, development and approval of targeted therapies, and development of combination therapies targeting multiple pathways.

Agenda

Welcome

Mark B. McClellan

Former Brookings Expert

Mark McClellan is a senior fellow and director of the Health Care Innovation and Value Initiative at Brookings. He has written a number of publications on care delivery reform, physician payment reform, and accountable care implementation in the U.S. and abroad.

Panel 1: Data Submission Standards and Evidence Requirements

R

Robert Temple

Deputy Director for Clinical Science, Center for Drug Evaluation and Research - U.S. Food and Drug Administration

Panel 2: Blinded Independent Central Review of PFS Endpoints

L

Lori Dodd

National Institute of Allergy and Infectious Diseases

Keynote Address

Panel 3: Accelerating Development and Approval of Targeted Cancer Therapies

Panel 4: Development of Two Novel Therapeutics Targeting Multiple Pathways

A

Adam Clark

Director, Scientific and Federal Affairs, Faster Cures

J

Janet Woodcock

Director, Center for Drug Evaluation and Research - US Food and Drug Administration

Summary and Closing Remarks

Mark B. McClellan

Former Brookings Expert

Mark McClellan is a senior fellow and director of the Health Care Innovation and Value Initiative at Brookings. He has written a number of publications on care delivery reform, physician payment reform, and accountable care implementation in the U.S. and abroad.

More Information

More

Get a weekly events calendar from Brookings